We have updated the Onselex Pharmaceuticals investor presentation by adding our IPO Roadmap as a supplemental section at the end of the deck, creating a more complete and efficient single presentation.

The main presentation highlights ONX-1006:

• Strong preclinical efficacy, Slide 4
• Preclinical non-toxic profile supported by NOAEL findings, Slide 5
• Sustained and extended dosing potential, Slide 6

Our near-term objective remains advancing ONX-1006 from a robust preclinical package into human clinical validation for Stage IV pancreatic cancer.

The IPO Roadmap is intended to outline our strategic objectives. Actual timing may shift depending on financing, regulatory progress, clinical execution, and market conditions.